STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 81 filers reported holding STEMLINE THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $353,000 | -59.1% | 73,061 | -10.2% | 0.00% | -100.0% |
| Q4 2019 | $864,000 | +159.5% | 81,351 | +154.6% | 0.00% | – |
| Q3 2019 | $333,000 | +17.3% | 31,948 | +72.1% | 0.00% | – |
| Q2 2019 | $284,000 | +6.8% | 18,561 | -9.8% | 0.00% | – |
| Q1 2019 | $266,000 | +100.0% | 20,580 | +46.6% | 0.00% | – |
| Q4 2018 | $133,000 | -81.8% | 14,041 | -69.2% | 0.00% | -100.0% |
| Q2 2018 | $732,000 | +293.5% | 45,598 | +172.1% | 0.00% | – |
| Q3 2017 | $186,000 | +51.2% | 16,756 | +45.9% | 0.00% | – |
| Q4 2016 | $123,000 | +70.8% | 11,483 | +8.7% | 0.00% | – |
| Q2 2016 | $72,000 | -41.9% | 10,567 | +0.2% | 0.00% | – |
| Q2 2015 | $124,000 | -69.5% | 10,545 | -55.7% | 0.00% | – |
| Q4 2014 | $406,000 | +161.9% | 23,809 | +125.5% | 0.00% | – |
| Q2 2014 | $155,000 | -77.5% | 10,557 | -68.8% | 0.00% | -100.0% |
| Q1 2014 | $689,000 | -19.1% | 33,812 | -22.2% | 0.00% | 0.0% |
| Q4 2013 | $852,000 | – | 43,472 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
| Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
| NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
| Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
| Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
| KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
| Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
| Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
| J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |